In January 2026, Eli Lilly closed its $1.2 billion acquisition of Ventyx Biosciences. The deal brought one drug into Lilly's portfolio: parunoflast (VTX3232), an oral NLRP3 inflammasome inhibitor.
Lilly already owned tirzepatide — marketed as Mounjaro and Zepbound — the GLP-1/GIP receptor agonist that has become the most commercially successful obesity drug in history.
One company now owns both halves of a story that nobody in the company appears to be reading.
The Two Mechanisms
Secondary hypogonadism in obese men is driven by two interlocking systems. The first is metabolic: insulin resistance, leptin resistance, and aromatase overactivity convert testosterone to estradiol in adipose tissue, suppress hypothalamic kisspeptin signaling, and blunt GnRH pulsatility. GLP-1 receptor agonists address this mechanism. A systematic review presented at ENDO 2026 confirmed: semaglutide restored testosterone by ~28% and liraglutide by ~34% in men with obesity and functional hypogonadism. Tirzepatide's data is stronger still — Cannarella's study showed 100% reversal of hypogonadism with tirzepatide in obese men.
The second mechanism is inflammatory. The NLRP3 inflammasome — an intracellular danger sensor — drives chronic sterile inflammation in obesity. When activated, it assembles caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their active forms. These cytokines do not merely float in the bloodstream. They act at specific sites that matter for the HPG axis:
NLRP3-driven microglial activation causes gliosis in the arcuate nucleus — the region where kisspeptin neurons reside. MRI-measured gliosis correlates inversely with testosterone, independent of BMI.
IL-1β suppresses CYP450 steroidogenic enzymes in Leydig cells, reduces testosterone synthesis, and drives pyroptotic cell death across four testicular cell types — including spermatogonial stem cells.
GLP-1 agonists address the metabolic half. NLRP3 inhibitors address the inflammatory half. Lilly now owns both.
What Parunoflast Does in Humans
At the American College of Cardiology meeting in March 2026, Lilly presented Phase 2a results for parunoflast in obesity. The trial was a 12-week, double-blind, placebo-controlled study with four arms: parunoflast alone, semaglutide alone, parunoflast plus semaglutide, and placebo.
The inflammatory results were striking. hsCRP dropped ~80% within the first week and stayed down for 12 weeks. IL-6 fell to levels associated with reduced cardiovascular risk. Fibrinogen, ESR, and lipoprotein(a) all decreased. The combination of parunoflast plus semaglutide beat semaglutide alone on every inflammatory marker.
The metabolic result was equally significant for what it wasn't: parunoflast produced no weight loss. Not alone, not in combination. The inflammation resolved while the adiposity remained. This is the class effect — Rezera's ruvonoflast (RESOLVE-1) showed the same pattern: primary inflammation endpoint met, no impact on body weight.
Inflammation without adiposity change. That is the dissociation that matters. It means you can suppress the inflammatory arm of HPG disruption without waiting for weight loss — and it means the inflammatory arm is not merely a downstream consequence of being fat.
What Parunoflast Does in the Brain
Separately, parunoflast was tested in a Phase 2a trial for Parkinson's disease — 10 patients, 28 days, 40mg daily. The results confirmed what the endocrine question requires: this drug gets into the brain. CSF concentrations exceeded the IC90 for NLRP3 inhibition for a full 24 hours post-dose. IL-1β and IL-18 decreased. MDS-UPDRS scores improved across motor and non-motor domains.
And in preclinical work, VTX3232 reduced both GFAP+ astrocytes and IBA1+ microglia in the arcuate nucleus of diet-induced obese mice — the exact brain region where kisspeptin neurons control GnRH pulsatility and, downstream, LH secretion and testosterone production.
The drug enters the brain. It engages its target in CSF. It reduces gliosis in kisspeptin neuron territory. And nowhere in any of these studies — obesity, Parkinson's, preclinical — did anyone measure testosterone, LH, FSH, kisspeptin, or any reproductive endpoint.
The Feedback Loop Nobody Is Testing
The case for a reproductive signal is not speculative. It is mechanistically mapped across at least four independent papers published between 2023 and 2026:
| Finding | Tissue | Source |
|---|---|---|
| KP-10 suppresses NLRP3 and caspase-1 in microglia via dual mechanism (inflammasome inhibition + BAG3-dependent aggrephagy) | Brain (microglia) | Neuropeptides, 2026 |
| KP-54 suppresses NLRP3 via AMPK phosphorylation; GPR54 receptor downregulated under inflammation | Lung (macrophages) | PMID 42418889, Aug 2026 |
| Kisspeptin suppresses NLRP3 and pyroptosis at the maternal-fetal interface | Placenta | Int J Mol Sci, 2023 |
| Icariin (plant-derived) inhibits NLRP3/caspase-1/GSDMD pathway in Leydig cells, restores testosterone in obese mice | Testes (Leydig cells) | Int Immunopharmacol, 2025 |
The first paper is the one that should make endocrinologists sit up. Kisspeptin-10 — the truncated form of the neuropeptide that controls GnRH pulsatility — directly suppresses NLRP3 in microglia. The same cell type that drives hypothalamic gliosis. The same cell type that VTX3232 reduces in the arcuate nucleus. And when NLRP3 activation is already high (as in metabolic inflammation), the GPR54 receptor that senses kisspeptin gets downregulated — meaning the neurons lose sensitivity to their own anti-inflammatory brake.
This is a feedforward loop: inflammation suppresses kisspeptin signaling, which removes kisspeptin's suppression of NLRP3, which increases inflammation, which further suppresses kisspeptin. An NLRP3 inhibitor doesn't just reduce inflammation — it potentially restores the endogenous kisspeptin-NLRP3 brake that metabolic disease removed.
What Lilly Owns
Lilly tested parunoflast in combination with semaglutide — a competitor's GLP-1 RA — and proved the combination beat either drug alone on inflammation. They own the GLP-1 RA with the strongest testosterone restoration data. They have not combined their own two drugs. They have not measured what the mechanism predicts those drugs would do together to the HPG axis.
The Question That Isn't Being Asked
There is a man. He is 42, obese, with testosterone of 220 ng/dL, elevated hsCRP, and intact testes. His HPG axis is being suppressed from two directions: metabolically (insulin resistance, leptin resistance, aromatase excess) and inflammatorily (NLRP3-driven hypothalamic gliosis, testicular IL-1β, spermatogonial pyroptosis). He is the intersection of two drug portfolios that now sit inside one company.
What happens if you give him both?
Tirzepatide reverses the metabolic half — insulin sensitivity improves, weight drops, aromatase activity falls, kisspeptin neurons get metabolic permission to fire again. Parunoflast reverses the inflammatory half — microglial activation drops, astrocytic gliosis resolves, Leydig cells stop dying, the kisspeptin-NLRP3 feedforward loop breaks. Together, you don't just address one arm of suppression. You address both, and you potentially restore the endogenous brake that prevents future inflammatory suppression.
The systematic reviews are accumulating. The mechanistic reviews are mapping it. The clinical reviews are naming hypothalamic gliosis as a cause of hypogonadism independent of adiposity. The basic science is showing kisspeptin directly suppresses NLRP3 in microglia.
And the company that owns both halves of the therapeutic answer is running trials that measure hsCRP, IL-6, body weight, and MDS-UPDRS scores — while the reproductive axis sits in the blind spot between two clinical development programs that, if they ever talked to each other, would have reason to add four blood draws and a questionnaire.
Four draws. Testosterone, LH, FSH, SHBG. That is what separates a cardiovascular inflammation trial from a reproductive medicine discovery. The mechanism is published. The drugs exist. The company is one. The question is zero.